TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3545246

Group type: EXPERIMENTAL
Intervention: Functioning transcutaneous electrical nerve stimulators (TENS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and functioning TENS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and placebo TENS
Number of subjects: 100
Study: 2571492

Group type: EXPERIMENTAL
Intervention: Lefetamine administered to opiate addicts with acute withdrawal syndrome
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lefetamine tested in naloxone and pentazocine tests
Number of subjects: 30
Study: 30470457

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program (10 sessions of 45 minutes each, one per week) focusing on memory, orientation, language, praxis, gnosis, calculation, perception, logical reasoning, attention-concentration, and programming.
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (no cognitive stimulation program).
Number of subjects: 201
Study: 30789018

Group type: EXPERIMENTAL
Intervention: Placebo dry powder inhaler
Number of subjects: 537
Study: 29956905

Group type: EXPERIMENTAL
Intervention: Guasha therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Sham scraping
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study: 26512691

Group type: EXPERIMENTAL
Intervention: Low-fat milk with added fructose containing sugars (50th percentile of fructose consumption)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-fat milk sweetened with glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsweetened low-fat milk (control group)
Number of subjects: 0
Study: 24124482

Group type: EXPERIMENTAL
Intervention: Isoflurane (I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of ketamine (IK)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of propofol (IP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflurane with CRI of fentanyl (IF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between groups IK and IF
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparison between groups IF and IK
Number of subjects: 80
Study: 21088594

Group type: EXPERIMENTAL
Intervention: Intubation model simulator training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Computer-based DVD training
Number of subjects: 60
Study: 19475666

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Memantine + CIAT
Number of subjects: 28

Group type: COMPARATOR
Intervention: CIAT
Number of subjects: 28

Group type: COMPARATOR
Intervention: Switching to Memantine from Placebo
Number of subjects: 28
Study: 17116670

Group type: EXPERIMENTAL
Intervention: Micafungin (Mycamine)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 35
Study: 12766899

Group type: EXPERIMENTAL
Intervention: Gd‐BOPTA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Gd‐DTPA
Number of subjects: 21
Study: 10321522

Group type: EXPERIMENTAL
Intervention: PUVA-cream therapy
Number of subjects: 12

Group type: COMPARATOR
Intervention: PUVA-bath therapy
Number of subjects: 12
Study: 9185262

Group type: EXPERIMENTAL
Intervention: Artemether-Azithromycin (300 mg artemether + 500 mg azithromycin, followed by 250 mg azithromycin at 24 and 48 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Artemether-Doxycycline (300 mg artemether + 100 mg doxycycline as initial doses, followed by 100 mg artemether + 100 mg doxycycline at 12 hours later, then 100 mg doxycycline every 12 hours for another 4 days)
Number of subjects: 60
Study: 1926059

Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 100 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 200 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dermatan sulfate (DS) 400 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Heparin 5,000 IU
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6760652

Group type: EXPERIMENTAL
Intervention: Natamycin vaginal tablets for 10 days, partners treated with natamycin cream
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo cream for partners
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups (treated and placebo)
Number of subjects: 33
Study: 31152113

Group type: EXPERIMENTAL
Intervention: Rude environment (incivility)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Normal environment (control)
Number of subjects: 76
Study: 28215166

Group type: EXPERIMENTAL
Intervention: Seaweed polysaccharides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current anti-inflammatory drugs
Number of subjects: 0
Study: 25956843

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L‐AmB) inhalation
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (no L‐AmB inhalation)
Number of subjects: 127
Study: 23614586

Group type: EXPERIMENTAL
Intervention: Health-education package (including a cartoon video)
Number of subjects: 1718

Group type: COMPARATOR
Intervention: Control package (health-education poster)
Number of subjects: 1718
Study: 22066824

Group type: EXPERIMENTAL
Intervention: Resistance training with soy protein based supplementation (RTS-G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resistance training without supplementation (RT-G)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lifestyle education only (LE-G)
Number of subjects: 40
Study: 19749201

Group type: COMPARATOR
Intervention: Impedance cardiography (ICG) measures during supine rest and HUT test.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Baseline cardiovascular measurements (CI, EDI, LVWI) using ICG.
Number of subjects: 86
Study: 16467677

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin 0.5% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin 0.3% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin 0.3% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Number of subjects: 12
Study: 15849397

Group type: EXPERIMENTAL
Intervention: Chronic hepatitis B (CBH)
Number of subjects: 47
Study: 15512472

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Intrauterine contraceptive device (IUCD)
Number of subjects: 56
Study: 9124829

Group type: EXPERIMENTAL
Intervention: Foscarnet (intravenous dosages for 10 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 27
Study: 1425160

Group type: EXPERIMENTAL
Intervention: Insulin therapy (6-20 IU at bedtime plus oral drugs)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo-insulin
Number of subjects: 38
Study: 6737950

Group type: EXPERIMENTAL
Intervention: Human growth hormone (12 U hGH/m2 per week)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Age-matched control group (no specific intervention mentioned)
Number of subjects: 6
Study: 30393077

Group type: EXPERIMENTAL
Intervention: Baseline dietary intake assessment using Automated Self‐Administered 24‐Hour Recall; participants reported food intake on 3 nonconsecutive days.
Number of subjects: 37
Study: 29762043

Group type: EXPERIMENTAL
Intervention: Fish oil 1.6 g/day for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 28892575

Group type: EXPERIMENTAL
Intervention: Albendazole during pregnancy
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Praziquantel during pregnancy
Number of subjects: 1215

Group type: EXPERIMENTAL
Intervention: Quarterly albendazole from age 15 months to 5 years
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Placebo from age 15 months to 5 years
Number of subjects: 1215
Study: 25646027

Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan or temozolomide
Number of subjects: 37
Study: 24040856

Group type: EXPERIMENTAL
Intervention: Ephedrine (0.02 mg×kg‐1×min‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Phenylephrine (0.25 μg×kg‐1×min‐1)
Number of subjects: 60
Study: 21440548

Group type: EXPERIMENTAL
Intervention: EGF genotype G/G
Number of subjects: 816

Group type: COMPARATOR
Intervention: EGF genotype A/A
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Subjects with at least one G allele
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: EGF G/G genotype with above-median serum levels of EGF
Number of subjects: 816

Group type: EXPERIMENTAL
Intervention: Prediction model including EGF genotype
Number of subjects: 816
Study: 18178070

Group type: EXPERIMENTAL
Intervention: ITRA‐GSMP capsule (50mg itraconazole)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sporanox capsule (100mg itraconazole)
Number of subjects: 8
Study: 17000452

Group type: EXPERIMENTAL
Intervention: 5 mg pilocarpine (Salagen) four times daily for 12 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo tablet
Number of subjects: 44
Study: 14525814

Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze inadequate plexus anesthesia
Number of subjects: 65170

Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze difficult emergence from general anesthesia
Number of subjects: 65170

Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze intubation difficulties
Number of subjects: 65170

Group type: EXPERIMENTAL
Intervention: Statistical process control methods applied to analyze medication errors
Number of subjects: 65170
Study: 11038436

Group type: EXPERIMENTAL
Intervention: Celgene thalidomide capsules (200 mg) under fasted conditions
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Celgene thalidomide capsules (200 mg) with food
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Serral thalidomide tablets (200 mg) under fasted conditions
Number of subjects: 13
Study: 9068325

Group type: EXPERIMENTAL
Intervention: Propacetamol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metamizol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External cooling
Number of subjects: 20
Study: 8452109

Group type: EXPERIMENTAL
Intervention: Carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks
Number of subjects: 30
Study: 3456377

Group type: EXPERIMENTAL
Intervention: Sealed lesions
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control lesions
Number of subjects: 14
Study: 30425351

Group type: EXPERIMENTAL
Intervention: Home-based specialised palliative care and dyadic psychological intervention
Number of subjects: 258
Study: 27211082

Group type: EXPERIMENTAL
Intervention: Calcium plus cholecalciferol (600 mg/d + 200 IU/d)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 24897082

Group type: EXPERIMENTAL
Intervention: Dalbavancin (intravenously on days 1 and 8)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Vancomycin (intravenously for at least 3 days, with an option to switch to oral linezolid)
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Vancomycin-linezolid
Number of subjects: 1312
Study: 22424015

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 384

Group type: COMPARATOR
Intervention: Vascular brachytherapy (VBT)
Number of subjects: 384
Study: 21029622

Group type: EXPERIMENTAL
Intervention: Drug eluting stent
Number of subjects: 189
Study: 18409107

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (optimal arousal regulation)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention (poor arousal regulation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Attention control (no biofeedback intervention)
Number of subjects: 9
Study: 15889586

Group type: EXPERIMENTAL
Intervention: Alpha-theta neurofeedback
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) biofeedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 24
Study: 12610841

Group type: EXPERIMENTAL
Intervention: Bobath concept (neurodevelopmental treatment)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 15
Study: 10826567

Group type: EXPERIMENTAL
Intervention: 75 mg acetylsalicylic acid (ASA) daily
Number of subjects: 18790

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Lower diastolic BP target groups (< or = 80 mmHg)
Number of subjects: 18790

Group type: EXPERIMENTAL
Intervention: Lower diastolic BP target groups
Number of subjects: 18790
Study: 8075614

Group type: EXPERIMENTAL
Intervention: Horacort (2 puffs bd) for 8 weeks in asthma patients
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Horacort (2 puffs bd) for 4 weeks in allergic rhinitis patients
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pulmicort (control)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 47
Study: 2561518

Group type: EXPERIMENTAL
Intervention: LHRH (100 mcg) + TRH (200 mcg) + GHRH 1‐29NH2 (100 mcg) i.v. (Politest 'B')
Number of subjects: 20

Group type: COMPARATOR
Intervention: LHRH (100 mcg) + TRH (200 mcg) + Human Insulin (0.1 UI/kg) i.v. (Politest 'A')
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHRH 1‐29NH2 (100 mcg) i.v. (GHRH-TEST)
Number of subjects: 20
Study: 998673

Group type: EXPERIMENTAL
Intervention: Radical hysterectomy with pelvic lymph node dissection
Number of subjects: 446

Group type: COMPARATOR
Intervention: Full-course radiation therapy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 446
Study: 31863582

Group type: EXPERIMENTAL
Intervention: Digital storytelling intervention (film about quitting smoking)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Attention-control film (women talking about living with HIV)
Number of subjects: 53
Study: 30580572

Group type: EXPERIMENTAL
Intervention: Baseline DKK1 concentration
Number of subjects: 5165

Group type: EXPERIMENTAL
Intervention: Change in DKK1 and levels at 1 month
Number of subjects: 5165

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5165
Study: 28350714

Group type: EXPERIMENTAL
Intervention: Multiple-transportable carbohydrate (2:1 glucose-fructose)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard isocaloric carbohydrate (glucose/maltodextrin only)
Number of subjects: 74
Study: 26231225

Group type: EXPERIMENTAL
Intervention: I-DECIDE website
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparator website (basic relationship and safety advice)
Number of subjects: 0
Study: 23059506

Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 787

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 787
Study: 20844068

Group type: EXPERIMENTAL
Intervention: Micronized ground ferric pyrophosphate (MGFePP)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Sodium iron edetate (NaFeEDTA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study: 18379224

Group type: EXPERIMENTAL
Intervention: LOW (100% < or = lactate threshold (LT) training)
Number of subjects: 18

Group type: COMPARATOR
Intervention: MIX (70% training at < or = LT and 30% at halfway (50%Delta) between the V O2 at LT and V O2peak)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LOW and MIX
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: LOW
Number of subjects: 18
Study: 16375890

Group type: EXPERIMENTAL
Intervention: Delta(9)‐THC 5 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 0.02 mg/kg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12576168

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 1422
Study: 10976542

Group type: EXPERIMENTAL
Intervention: 2% caprylocaproyl macrogolglycerides
Number of subjects: 12
Study: 9190776

Group type: EXPERIMENTAL
Intervention: Interpreter assisted counseling on HIV prevention
Number of subjects: 248

Group type: COMPARATOR
Intervention: No systematic counseling (control group)
Number of subjects: 248
Study: 1437958

Group type: EXPERIMENTAL
Intervention: Immediate mobilization
Number of subjects: 110

Group type: COMPARATOR
Intervention: 4 hours bed rest
Number of subjects: 110
Study: 3083785

Group type: EXPERIMENTAL
Intervention: MMC+5‐FU+lentinan (LNT)
Number of subjects: 166

Group type: COMPARATOR
Intervention: MMC+5‐FU
Number of subjects: 166
Study: 31014365

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training without any load (PRWIMT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training with a linear load (PRIMTLL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation associated with inspiratory muscle training with isocapnic voluntary hyperpnea (PRIMTIVH)
Number of subjects: 60
Study: 29554497

Group type: EXPERIMENTAL
Intervention: Vortioxetine (10-20 mg/day)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 493

Group type: COMPARATOR
Intervention: Vortioxetine (10-20 mg/day) and Agomelatine (25-50 mg/day)
Number of subjects: 493
Study: 26692296

Group type: EXPERIMENTAL
Intervention: Implementation intentions (forming if-then plans)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Self-affirmation (values essay)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Self-affirmation with social value affirmation
Number of subjects: 348
Study: 25512268

Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RIPostC)
Number of subjects: 46
Study: 22967863

Group type: EXPERIMENTAL
Intervention: Oral minocycline and artificial tears
Number of subjects: 60

Group type: COMPARATOR
Intervention: Artificial tears only
Number of subjects: 60
Study: 20884700

Group type: EXPERIMENTAL
Intervention: Multifaceted empowerment strategy (decision aid, nurse support, reimbursement offer)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Control group (standard care for in vitro fertilisation)
Number of subjects: 308
Study: 17874331

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral clodronate 2,400 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral clodronate 3,200 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 15654690

Group type: EXPERIMENTAL
Intervention: Strength training (knee extension and leg-press exercises) performed three times per week for 14 weeks
Number of subjects: 0
Study: 12232493

Group type: EXPERIMENTAL
Intervention: Sulfur baths
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (spa therapy)
Number of subjects: 38
Study: 10400838

Group type: EXPERIMENTAL
Intervention: 200 microgram budesonide once daily
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: 400 microgram budesonide once daily (reduced to 200 microgram at week 6)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 7724772

Group type: EXPERIMENTAL
Intervention: Resovist (8 mumol Fe/kg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Resovist (4, 8, and 16 mumol Fe/kg)
Number of subjects: 33
Study: 2066453

Group type: EXPERIMENTAL
Intervention: Desipramine treatment
Number of subjects: 12
Study: 6340009

Group type: EXPERIMENTAL
Intervention: Oxmetidine (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cimetidine (1 g/day)
Number of subjects: 30
Study: 31232088

Group type: EXPERIMENTAL
Intervention: Nature sound group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Earplug group
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study: 30226143

Group type: EXPERIMENTAL
Intervention: Chikungunya virus infection
Number of subjects: 509
Study: 26739725

Group type: EXPERIMENTAL
Intervention: Patient-centred care (PCC)
Number of subjects: 478
Study: 25316572

Group type: EXPERIMENTAL
Intervention: Ipragliflozin (Suglat®)
Number of subjects: 0
Study: 22985610

Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg the night before surgery and 400 mg twice daily for 4 to 6 days post-surgery)
Number of subjects: 112

Group type: COMPARATOR
Intervention: No amiodarone (control group)
Number of subjects: 112
Study: 19785632

Group type: COMPARATOR
Intervention: Prone position during quiet sleep (QS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Prone position during active sleep (AS)
Number of subjects: 31
Study: 17985384

Group type: EXPERIMENTAL
Intervention: High dose intracoronary adenosine
Number of subjects: 51
Study: 16131694

Group type: EXPERIMENTAL
Intervention: 6% CHO
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 3% CHO
Number of subjects: 5

Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 5
Study: 12377914

Group type: EXPERIMENTAL
Intervention: Cemented Mallory‐Head total hip prosthesis
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cementless Mallory‐Head total hip prosthesis
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups (Cemented and Cementless)
Number of subjects: 250
Study: 10418906

Group type: EXPERIMENTAL
Intervention: Intradermal Mycobacterium vaccae vaccine (MV)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (HBV)
Number of subjects: 35
Study: 7473472

Group type: EXPERIMENTAL
Intervention: Deflazacort (24 mg daily or 48 mg alternate day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: 6‐methylprednisolone (16 mg daily or 32 mg alternate day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 31

Group type: COMPARATOR
Intervention: 6‐methylprednisolone
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 31
Study: 2290600

Group type: EXPERIMENTAL
Intervention: Nimesulide (2 suppositories a day for 7 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Flurbiprofen (2 suppositories a day for 7 days)
Number of subjects: 100
Study: 471857

Group type: EXPERIMENTAL
Intervention: i.v. domperidone (0.35 and 0.7 mg/kg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: i.v. or oral domperidone
Number of subjects: 59